Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis
Conclusion:
The current meta-analysis provides new evidence on different doses of canagliflozin as an antihypertensive agent in T2DM complicated by hypertension; however, LDL-C and the risk of UTI should be monitored.
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL ARTICLES Source Type: research
More News: Canagliflozin | Cardiology | Cholesterol | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Hypertension | Invokana | Sodium | Study | Urinary Tract Infections